Comparative Pharmacology
Head-to-head clinical analysis: REMODULIN versus VERTAVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REMODULIN versus VERTAVIS.
REMODULIN vs VERTAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Category C
Category C
Prostacyclin Vasodilator
Prostacyclin Vasodilator